サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427989

希少神経疾患治療の世界市場レポート 2024

Rare Neurological Disease Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
希少神経疾患治療の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

希少神経疾患治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.2%の年間複合成長率（CAGR）で134億1,000万米ドルに成長すると予想されています。予測期間で予想される成長は、診断ツールの改善、精密医療の進歩、患者中心の医薬品開発アプローチの開発、現実世界の証拠の統合、患者サポートのための遠隔医療の使用、および医療への移行によるものと考えられます。個別化された治療法。予測期間中に予想される注目すべき動向には、技術革新、創薬における人工知能の応用、データセキュリティのためのブロックチェーンの実装、創薬における機械学習の利用などが含まれます。

希少神経疾患治療市場の予想される成長は、希少な神経疾患の蔓延によって促進されると予想されます。有病率が低いことを特徴とするこれらの疾患には、ハンチントン病、筋萎縮性側索硬化症（ALS）、レット症候群、さまざまな形態の筋ジストロフィーなどの疾患が含まれます。希少な神経疾患の治療には、症状を管理し、病気の進行を遅らせ、罹患者の生活の質を向上させるための多様なアプローチの採用が含まれます。たとえば、BioMed Central Ltd.が2023年1月に報告したように、レット症候群の集団有病率は、サンプルサイズ957万人の女性のうち、女性10万人当たり7.1人と決定され、確認された症例は合計673人でした。したがって、希少な神経疾患の蔓延は、希少神経疾患治療市場の成長の重要な推進力です。

予想されるヘルスケア費の増加は、希少神経疾患治療市場の成長を促進する態勢が整っています。ヘルスケア支出には、医療サービスの提供に関連するすべての費用が含まれており、健康関連の活動に重点が置かれています。ヘルスケアへの支出の増加は、調査、開発、専門的なケアへのアクセス、希少な神経疾患の治療とサポートの進歩に不可欠な認識を支援します。 2022年12月、メディケア・メディケイド・サービスセンターによると、米国のヘルスケア費は2021年に2.7％増の1人当たり1万2,914米ドルとなり、総額は4兆3,000億米ドルとなった。ヘルスケア支出は国のGDPの18.3%を占めました。したがって、ヘルスケア費の急増が希少神経疾患治療市場の成長に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の希少神経疾患治療市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 生物製剤
  • 低分子
  • 世界の希少神経疾患治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 認知行動療法
  • 対人関係心理療法
  • サイバーナイフ
  • その他の治療法
  • 世界の希少神経疾患治療市場、投与方法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 注射可能
  • その他の投与方法
  • 世界の希少神経疾患治療市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アイカルディ症候群
  • アイカルディ・グティエール症候群
  • 反射性交感神経性ジストロフィー症候群
  • バッタリア・ネリ症候群
  • クロイツフェルト・ヤコブ病
  • 失認症
  • その他の疾患
  • 世界の希少神経疾患治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局とドラッグストア
  • オンライン薬局

第7章 地域および国の分析

  • 世界の希少神経疾患治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の希少神経疾患治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 希少神経疾患治療市場の競合情勢
  • 希少神経疾患治療市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd
    • Bayer AG
    • Merck &Co. Inc.

第31章 その他の大手および革新的な企業

  • AbbVie Inc.
  • Novartis AG
  • Sanofi-Aventis SA
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Medtronic PLC
  • Teva Pharmaceutical Industries Ltd.
  • CSL Limited
  • Biogen Inc.
  • UCB SA
  • Eisai Co. Ltd.
  • Otsuka Pharmaceutical Co. Ltd.
  • Jazz Pharmaceuticals PLC

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13833

Treatment for rare neurological diseases involves medical interventions and therapies with the goal of managing symptoms, slowing disease progression, and enhancing the quality of life for individuals affected by these uncommon conditions. Rare neurological diseases encompass disorders that affect the nervous system, including the brain, spinal cord, and peripheral nerves.

The primary types of treatment for rare neurological diseases involve drugs, including biologics and small molecules. Biologics, derived from living organisms such as proteins, antibodies, or nucleic acids, play a crucial role in treating rare neurological diseases. Examples include enzyme replacement therapies for lysosomal storage disorders and monoclonal antibodies for immune-mediated neurological disorders. Various therapies, such as cognitive behavioral therapy, interpersonal psychotherapy, and cyberknife, are administered through oral and injectable modes to address specific conditions such as Aicardi syndrome, Aicardi Goutieres syndrome, reflex sympathetic dystrophy syndrome, Battaglia-Neri syndrome, Creutzfeldt-Jakob disease, agnosia, and others. Medications are distributed through channels including hospitals, retail pharmacies, drug stores, and online pharmacies.

The rare neurological diseases treatment market research report is one of a series of new reports from The Business Research Company that provides rare neurological diseases treatment market statistics, including the rare neurological diseases treatment industry's global market size, regional shares, competitors with a rare neurological diseases treatment market share, detailed rare neurological diseases treatment market segments, rare neurological diseases treatment market trends and opportunities, and any further data you may need to thrive in the rare neurological diseases treatment industry. This rare neurological diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rare neurological disease treatment market size has grown strongly in recent years. It will grow from $8.98 billion in 2023 to $9.79 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The increase observed in the historical period can be attributed to the utilization of biosimilars in rare disease treatment, the globalization of clinical trials, healthcare reimbursement policies, designations of orphan drugs, and advancements in genetic research.

The rare neurological disease treatment market size is expected to see strong growth in the next few years. It will grow to $13.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be attributed to improved diagnostic tools, advancements in precision medicine, the development of patient-centric drug development approaches, the integration of real-world evidence, the use of telemedicine for patient support, and a shift towards personalized therapies. Noteworthy trends expected during the forecast period include technological innovations, the application of artificial intelligence in drug discovery, the implementation of blockchain for data security, and the utilization of machine learning in drug discovery.

The anticipated growth of the rare neurological disease treatment market is expected to be driven by the prevalence of rare neurological diseases. These conditions, characterized by low prevalence, encompass disorders such as Huntington's disease, amyotrophic lateral sclerosis (ALS), Rett syndrome, and various forms of muscular dystrophy. Treating rare neurological diseases involves employing diverse approaches to manage symptoms, slow disease progression, and enhance the quality of life for affected individuals. For example, as reported in January 2023 by BioMed Central Ltd., the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a sample size of 9.57 million women, with a total of 673 confirmed cases. Therefore, the prevalence of rare neurological diseases is a significant driver for the growth of the rare neurological disease treatment market.

The anticipated rise in healthcare expenditures is poised to fuel the growth of the rare neurological disease treatment market. Healthcare expenditures encompass all costs related to providing health services and focus on health-related activities. Increased spending in healthcare supports research, development, specialized care access, and awareness crucial for advancing treatments and support for rare neurological diseases. In December 2022, according to the Centers for Medicare & Medicaid Services, spending on healthcare in the United States increased by 2.7 percent to $12,914 per person in 2021, totaling $4.3 trillion. Healthcare spending accounted for 18.3 percent of the country's GDP. Hence, the surge in healthcare expenditures is contributing to the growth of the rare neurological disease treatment market.

A noteworthy trend gaining traction in the rare neurological disease treatment market is the development of orphan pharmaceuticals. Key companies in the sector are directing their efforts towards creating innovative and specialized treatments to solidify their market positions. For instance, in April 2023, French orphan drug development company Orphalan SA introduced Cuvrior, a novel trientine tetrahydrochloride (TETA-4HCl), in the European market. Cuvrior is commercially available for treating adult patients with stable Wilson disease who have undergone copper reduction therapy and exhibited tolerance to D-penicillamine. This drug received approval from the United States Food and Drug Administration (FDA) and was granted orphan drug exclusivity (ODE) in April 2022 for this specific patient population.

Major players in the rare neurological disease treatment market are placing a strong emphasis on product innovation, including rare disease drug development solutions, to advance therapeutic options and enhance the quality of life for patients affected by rare neurological diseases. Developing treatments for rare neurological diseases necessitates targeted research into specific disease mechanisms and the exploration of innovative therapeutic approaches, such as gene therapies or personalized medicine, to address the complex nature of these conditions. For instance, in February 2023, US-based pharmaceutical company Reata Pharmaceuticals Inc. received approval from the United States Food and Drug Administration (USFDA) for Skyclarys, a drug designed to treat Friedreich's ataxia, a rare neurological disease. Skyclarys represents an experimental medication addressing unmet needs in treating rare neurological conditions by targeting intricate disease mechanisms. It is undergoing rigorous clinical evaluation for its efficacy and safety profiles.

In August 2021 US-based pharmaceutical company Harmony Biosciences acquired HBS-102, an MCHR1 antagonist, from ConSynance Therapeutics Inc. for $3.5 million. This acquisition aims to enhance Harmony Biosciences' position as a leading company in treating rare neurological diseases. The addition of HBS-102 to Harmony Biosciences' pipeline signifies a crucial expansion beyond its flagship product, WAKIX, providing a potential treatment option for narcolepsy, a rare disease. ConSynance Therapeutics Inc. is a US-based company focused on developing innovative therapeutics for various conditions, including rare neurological disorders.

Major companies operating in the rare neurological disease treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., CSL Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., Kedrion Biopharma Inc., Merz Pharma GmbH & Co. KGaA, Harmony Biosciences Holdings Inc., Amicus Therapeutics Inc., Revance Therapeutics Inc., Aquestive Therapeutics Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Stoke Therapeutics Inc., Retrotope Inc.

North America was the largest region in the rare neurological disease's treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare neurological disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rare neurological disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare neurological disease treatment market consists of revenues earned by entities by providing supportive care services and neurodegenerative research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare neurological disease treatment market also includes sales of anticonvulsants, antidepressants, and beta blockers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Neurological Disease Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare neurological disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare neurological disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rare neurological disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Type: Biologics; Small Molecules
  • 2) By Therapy: Cognitive Behavioral Therapy; Interpersonal Psychotherapy; Cyberknife; Other Therapies
  • 3) By Mode Of Administration: Oral; Injectable; Other Modes Of Administration
  • 4) By Disorders: Aicardi Syndrome; Aicardi-Goutieres Syndrome; Reflex Sympathetic Dystrophy Syndrome; Battaglia-Neri Syndrome; Creutzfeldt Jakob Disease; Agnosia; Other Disorders
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies And Drug Store; Online Pharmacies
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Neurological Disease Treatment Market Characteristics

3. Rare Neurological Disease Treatment Market Trends And Strategies

4. Rare Neurological Disease Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Rare Neurological Disease Treatment Market Size and Growth

  • 5.1. Global Rare Neurological Disease Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Rare Neurological Disease Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Rare Neurological Disease Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Rare Neurological Disease Treatment Market Segmentation

  • 6.1. Global Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biologics
  • Small Molecules
  • 6.2. Global Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cognitive Behavioral Therapy
  • Interpersonal Psychotherapy
  • Cyberknife
  • Other Therapies
  • 6.3. Global Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectable
  • Other Modes Of Administration
  • 6.4. Global Rare Neurological Disease Treatment Market, Segmentation By Disorders, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Aicardi Syndrome
  • Aicardi-Goutieres Syndrome
  • Reflex Sympathetic Dystrophy Syndrome
  • Battaglia-Neri Syndrome
  • Creutzfeldt Jakob Disease
  • Agnosia
  • Other Disorders
  • 6.5. Global Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies And Drug Store
  • Online Pharmacies

7. Rare Neurological Disease Treatment Market Regional And Country Analysis

  • 7.1. Global Rare Neurological Disease Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Rare Neurological Disease Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Rare Neurological Disease Treatment Market

  • 8.1. Asia-Pacific Rare Neurological Disease Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Rare Neurological Disease Treatment Market

  • 9.1. China Rare Neurological Disease Treatment Market Overview
  • 9.2. China Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Rare Neurological Disease Treatment Market

  • 10.1. India Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Rare Neurological Disease Treatment Market

  • 11.1. Japan Rare Neurological Disease Treatment Market Overview
  • 11.2. Japan Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Rare Neurological Disease Treatment Market

  • 12.1. Australia Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Rare Neurological Disease Treatment Market

  • 13.1. Indonesia Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Rare Neurological Disease Treatment Market

  • 14.1. South Korea Rare Neurological Disease Treatment Market Overview
  • 14.2. South Korea Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Rare Neurological Disease Treatment Market

  • 15.1. Western Europe Rare Neurological Disease Treatment Market Overview
  • 15.2. Western Europe Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Rare Neurological Disease Treatment Market

  • 16.1. UK Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Rare Neurological Disease Treatment Market

  • 17.1. Germany Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Rare Neurological Disease Treatment Market

  • 18.1. France Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Rare Neurological Disease Treatment Market

  • 19.1. Italy Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Rare Neurological Disease Treatment Market

  • 20.1. Spain Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Rare Neurological Disease Treatment Market

  • 21.1. Eastern Europe Rare Neurological Disease Treatment Market Overview
  • 21.2. Eastern Europe Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Rare Neurological Disease Treatment Market

  • 22.1. Russia Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Rare Neurological Disease Treatment Market

  • 23.1. North America Rare Neurological Disease Treatment Market Overview
  • 23.2. North America Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Rare Neurological Disease Treatment Market

  • 24.1. USA Rare Neurological Disease Treatment Market Overview
  • 24.2. USA Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Rare Neurological Disease Treatment Market

  • 25.1. Canada Rare Neurological Disease Treatment Market Overview
  • 25.2. Canada Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Rare Neurological Disease Treatment Market

  • 26.1. South America Rare Neurological Disease Treatment Market Overview
  • 26.2. South America Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Rare Neurological Disease Treatment Market

  • 27.1. Brazil Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Rare Neurological Disease Treatment Market

  • 28.1. Middle East Rare Neurological Disease Treatment Market Overview
  • 28.2. Middle East Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Rare Neurological Disease Treatment Market

  • 29.1. Africa Rare Neurological Disease Treatment Market Overview
  • 29.2. Africa Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Rare Neurological Disease Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Rare Neurological Disease Treatment Market Competitive Landscape
  • 30.2. Rare Neurological Disease Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & Co. Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Rare Neurological Disease Treatment Market Other Major And Innovative Companies

  • 31.1. AbbVie Inc.
  • 31.2. Novartis AG
  • 31.3. Sanofi-Aventis SA
  • 31.4. Bristol-Myers Squibb Company
  • 31.5. AstraZeneca PLC
  • 31.6. GlaxoSmithKline PLC
  • 31.7. Takeda Pharmaceutical Company Limited
  • 31.8. Medtronic PLC
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. CSL Limited
  • 31.11. Biogen Inc.
  • 31.12. UCB S.A.
  • 31.13. Eisai Co. Ltd.
  • 31.14. Otsuka Pharmaceutical Co. Ltd.
  • 31.15. Jazz Pharmaceuticals PLC

32. Global Rare Neurological Disease Treatment Market Competitive Benchmarking

33. Global Rare Neurological Disease Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Rare Neurological Disease Treatment Market

35. Rare Neurological Disease Treatment Market Future Outlook and Potential Analysis

  • 35.1 Rare Neurological Disease Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Rare Neurological Disease Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Rare Neurological Disease Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer